Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Quantitative assessment and clinical relevance of kallikrein-related peptidase 5 mRNA expression in advanced high-grade serous ovarian cancer.

Gong W, Liu Y, Seidl C, Diamandis EP, Kiechle M, Drecoll E, Kotzsch M, Magdolen V, Dorn J.

BMC Cancer. 2019 Jul 15;19(1):696. doi: 10.1186/s12885-019-5901-0.

2.

Characterization of kallikrein-related peptidase 4 (KLK4) mRNA expression in tumor tissue of advanced high-grade serous ovarian cancer patients.

Gong W, Liu Y, Seidl C, Dreyer T, Drecoll E, Kotzsch M, Bronger H, Dorn J, Magdolen V.

PLoS One. 2019 Feb 27;14(2):e0212968. doi: 10.1371/journal.pone.0212968. eCollection 2019.

3.

Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer.

Wang P, Magdolen V, Seidl C, Dorn J, Drecoll E, Kotzsch M, Yang F, Schmitt M, Schilling O, Rockstroh A, Clements JA, Loessner D.

Br J Cancer. 2018 Oct;119(7):1-9. doi: 10.1038/s41416-018-0260-1. Epub 2018 Oct 5.

4.

Advanced high-grade serous ovarian cancer: inverse association of KLK13 and KLK14 mRNA levels in tumor tissue and patients' prognosis.

Dettmar L, Ahmed N, Kotzsch M, Diersch S, Napieralski R, Darmoul D, Schmitt M, Weichert W, Kiechle M, Dorn J, Magdolen V.

J Cancer Res Clin Oncol. 2018 Jun;144(6):1109-1118. doi: 10.1007/s00432-018-2623-7. Epub 2018 Mar 15.

PMID:
29546479
5.

Clinical relevance of kallikrein-related peptidase 9, 10, 11, and 15 mRNA expression in advanced high-grade serous ovarian cancer.

Geng X, Liu Y, Diersch S, Kotzsch M, Grill S, Weichert W, Kiechle M, Magdolen V, Dorn J.

PLoS One. 2017 Nov 2;12(11):e0186847. doi: 10.1371/journal.pone.0186847. eCollection 2017.

6.

Inverse association of rab31 and mucin-1 (CA15-3) antigen levels in estrogen receptor-positive (ER+) breast cancer tissues with clinicopathological parameters and patients' prognosis.

Kotzsch M, Kirchner T, Soelch S, Schäfer S, Friedrich K, Baretton G, Magdolen V, Luther T.

Am J Cancer Res. 2017 Sep 1;7(9):1959-1970. eCollection 2017.

7.

Plasmin(ogen) serves as a favorable biomarker for prediction of survival in advanced high-grade serous ovarian cancer.

Zhao S, Dorn J, Napieralski R, Walch A, Diersch S, Kotzsch M, Ahmed N, Hooper JD, Kiechle M, Schmitt M, Magdolen V.

Biol Chem. 2017 Jun 27;398(7):765-773. doi: 10.1515/hsz-2016-0282.

PMID:
27935848
8.

Clinical relevance of kallikrein-related peptidase 6 (KLK6) and 8 (KLK8) mRNA expression in advanced serous ovarian cancer.

Ahmed N, Dorn J, Napieralski R, Drecoll E, Kotzsch M, Goettig P, Zein E, Avril S, Kiechle M, Diamandis EP, Schmitt M, Magdolen V.

Biol Chem. 2016 Dec 1;397(12):1265-1276. doi: 10.1515/hsz-2016-0177.

9.

Assessment of kallikrein-related peptidase 5 (KLK5) protein expression in tumor tissue of advanced ovarian cancer patients by immunohistochemistry and ELISA: correlation with clinical outcome.

Dorn J, Yassouridis A, Walch A, Diamandis EP, Schmitt M, Kiechle M, Wang P, Drecoll E, Schmalfeldt B, Loessner D, Kotzsch M, Magdolen V.

Am J Cancer Res. 2015 Dec 15;6(1):61-70. eCollection 2016.

10.

Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.

Fuessel S, Erdmann K, Taubert H, Lohse-Fischer A, Zastrow S, Meinhardt M, Bluemke K, Hofbauer L, Fornara P, Wullich B, Baretton G, Magdolen V, Wirth MP, Kotzsch M.

BMC Cancer. 2014 Dec 18;14:974. doi: 10.1186/1471-2407-14-974.

11.

Association of tissue mRNA and serum antigen levels of members of the urokinase-type plasminogen activator system with clinical and prognostic parameters in prostate cancer.

Al-Janabi O, Taubert H, Lohse-Fischer A, Fröhner M, Wach S, Stöhr R, Keck B, Burger M, Wieland W, Erdmann K, Wirth MP, Wullich B, Baretton G, Magdolen V, Kotzsch M, Füssel S.

Biomed Res Int. 2014;2014:972587. doi: 10.1155/2014/972587. Epub 2014 Apr 29.

12.

A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer. Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor.

Ostheimer C, Bache M, Güttler A, Kotzsch M, Vordermark D.

Strahlenther Onkol. 2014 Mar;190(3):276-82. doi: 10.1007/s00066-013-0484-1. Epub 2013 Dec 11.

PMID:
24322994
13.

Clinical value of protein expression of kallikrein-related peptidase 7 (KLK7) in ovarian cancer.

Dorn J, Gkazepis A, Kotzsch M, Kremer M, Propping C, Mayer K, Mengele K, Diamandis EP, Kiechle M, Magdolen V, Schmitt M.

Biol Chem. 2014 Jan;395(1):95-107. doi: 10.1515/hsz-2013-0172.

PMID:
23999494
14.

Impact of expression of the uPA system in sarcomas.

Taubert H, Magdolen V, Kotzsch M.

Biomark Med. 2013 Jun;7(3):473-80. doi: 10.2217/bmm.12.105. Review.

PMID:
23734810
15.

Overexpression of the urokinase receptor splice variant uPAR-del4/5 in breast cancer cells affects cell adhesion and invasion in a dose-dependent manner and modulates transcription of tumor-associated genes.

Grismayer B, Sato S, Kopitz C, Ries C, Soelch S, Schmitt M, Baretton G, Krüger A, Luther T, Kotzsch M, Magdolen V.

Biol Chem. 2012 Dec;393(12):1449-55.

PMID:
23667902
16.

Downregulation of serine protease HTRA1 is associated with poor survival in breast cancer.

Lehner A, Magdolen V, Schuster T, Kotzsch M, Kiechle M, Meindl A, Sweep FC, Span PN, Gross E.

PLoS One. 2013 Apr 8;8(4):e60359. doi: 10.1371/journal.pone.0060359. Print 2013.

17.

Rab31 expression levels modulate tumor-relevant characteristics of breast cancer cells.

Grismayer B, Sölch S, Seubert B, Kirchner T, Schäfer S, Baretton G, Schmitt M, Luther T, Krüger A, Kotzsch M, Magdolen V.

Mol Cancer. 2012 Aug 24;11:62. doi: 10.1186/1476-4598-11-62.

18.

Stromal cell-associated expression of kallikrein-related peptidase 6 (KLK6) indicates poor prognosis of ovarian cancer patients.

Seiz L, Dorn J, Kotzsch M, Walch A, Grebenchtchikov NI, Gkazepis A, Schmalfeldt B, Kiechle M, Bayani J, Diamandis EP, Langer R, Sweep FC, Schmitt M, Magdolen V.

Biol Chem. 2012 Apr;393(5):391-401. doi: 10.1515/hsz-2011-0264.

PMID:
22505521
19.

Prognostic impact of mRNA levels of osteopontin splice variants in soft tissue sarcoma patients.

Hahnel A, Wichmann H, Greither T, Kappler M, Würl P, Kotzsch M, Taubert H, Vordermark D, Bache M.

BMC Cancer. 2012 Apr 2;12:131. doi: 10.1186/1471-2407-12-131.

20.

mRNA expression levels of the biological factors uPAR, uPAR-del4/5, and rab31, displaying prognostic value in breast cancer, are not clinically relevant in advanced ovarian cancer.

Kotzsch M, Dorn J, Doetzer K, Schmalfeldt B, Krol J, Baretton G, Kiechle M, Schmitt M, Magdolen V.

Biol Chem. 2011 Nov;392(11):1047-51. doi: 10.1515/BC.2011.166.

PMID:
21848504
21.

Combined mRNA expression levels of members of the urokinase plasminogen activator (uPA) system correlate with disease-associated survival of soft-tissue sarcoma patients.

Kotzsch M, Magdolen V, Greither T, Kappler M, Bache M, Lautenschläger C, Füssel S, Eckert AW, Luther T, Baretton G, Würl P, Taubert H.

BMC Cancer. 2011 Jun 25;11:273. doi: 10.1186/1471-2407-11-273.

22.

Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells.

Hahnel A, Wichmann H, Kappler M, Kotzsch M, Vordermark D, Taubert H, Bache M.

Radiat Oncol. 2010 Sep 17;5:82. doi: 10.1186/1748-717X-5-82.

23.

Prognostic relevance of tumour cell-associated uPAR expression in invasive ductal breast carcinoma.

Kotzsch M, Bernt K, Friedrich K, Luther E, Albrecht S, Gatzweiler A, Magdolen V, Baretton G, Zietz C, Luther T.

Histopathology. 2010 Sep;57(3):461-71. doi: 10.1111/j.1365-2559.2010.03644.x.

PMID:
20840675
24.

Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo.

Sato S, Kopitz C, Grismayer B, Beaufort N, Reuning U, Schmitt M, Luther T, Kotzsch M, Krüger A, Magdolen V.

Breast Cancer Res Treat. 2011 Jun;127(3):649-57. doi: 10.1007/s10549-010-1042-5. Epub 2010 Jul 16.

PMID:
20635136
25.

Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients.

Bache M, Kappler M, Wichmann H, Rot S, Hahnel A, Greither T, Said HM, Kotzsch M, Würl P, Taubert H, Vordermark D.

BMC Cancer. 2010 Apr 8;10:132. doi: 10.1186/1471-2407-10-132.

26.

Polyclonal antibodies against kallikrein-related peptidase 4 (KLK4): immunohistochemical assessment of KLK4 expression in healthy tissues and prostate cancer.

Seiz L, Kotzsch M, Grebenchtchikov NI, Geurts-Moespot AJ, Fuessel S, Goettig P, Gkazepis A, Wirth MP, Schmitt M, Lossnitzer A, Sweep FC, Magdolen V.

Biol Chem. 2010 Apr;391(4):391-401. doi: 10.1515/BC.2010.033.

PMID:
20180634
27.

Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients.

Taubert H, Würl P, Greither T, Kappler M, Bache M, Lautenschläger C, Füssel S, Meye A, Eckert AW, Holzhausen HJ, Magdolen V, Kotzsch M.

Br J Cancer. 2010 Feb 16;102(4):731-7. doi: 10.1038/sj.bjc.6605520. Epub 2010 Jan 5.

28.

Tumor suppressor KAI1 affects integrin alphavbeta3-mediated ovarian cancer cell adhesion, motility, and proliferation.

Ruseva Z, Geiger PX, Hutzler P, Kotzsch M, Luber B, Schmitt M, Gross E, Reuning U.

Exp Cell Res. 2009 Jun 10;315(10):1759-71. doi: 10.1016/j.yexcr.2009.01.007. Epub 2009 Jan 22.

PMID:
19371633
29.

Multitarget siRNA inhibition of antiapoptotic genes (XIAP, BCL2, BCL-X(L)) in bladder cancer cells.

Kunze D, Wuttig D, Fuessel S, Kraemer K, Kotzsch M, Meye A, Grimm MO, Hakenberg OW, Wirth MP.

Anticancer Res. 2008 Jul-Aug;28(4B):2259-63.

30.
31.

Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy.

Pawlinski R, Tencati M, Hampton CR, Shishido T, Bullard TA, Casey LM, Andrade-Gordon P, Kotzsch M, Spring D, Luther T, Abe J, Pohlman TH, Verrier ED, Blaxall BC, Mackman N.

Circulation. 2007 Nov 13;116(20):2298-306. Epub 2007 Oct 29.

32.

Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor.

Kotzsch M, Sieuwerts AM, Grosser M, Meye A, Fuessel S, Meijer-van Gelder ME, Smid M, Schmitt M, Baretton G, Luther T, Magdolen V, Foekens JA.

Breast Cancer Res Treat. 2008 Sep;111(2):229-40. Epub 2007 Oct 20.

PMID:
17952591
33.

[In vitro and in vivo evaluation of inhibitory nucleic acid constructs for specific therapy of human urinary bladder carcinoma].

Kunze D, Füssel S, Meye A, Wuttig D, Krämer K, Kotzsch M, Toma M, Schwenzer B, Kausch I, Jocham D, Hakenberg OW, Grimm MO, Wirth MP.

Urologe A. 2007 Sep;46(9):1289. German. No abstract available.

PMID:
17665160
34.

Are overexpressed alternative survivin transcripts in human bladder cancer suitable targets for siRNA-mediated in vitro inhibition?

Wuttig D, Kunze D, Fuessel S, Toma M, Stade J, Kotzsch M, Kappler M, Taubert H, Schwenzer B, Baretton G, Hakenberg OW, Meye A, Wirth MP.

Int J Oncol. 2007 Jun;30(6):1317-24.

PMID:
17487351
35.

Quantitative reverse transcription-PCR assay for detection of mRNA encoding full-length human tissue kallikrein 7: prognostic relevance of KLK7 mRNA expression in breast cancer.

Holzscheiter L, Biermann JC, Kotzsch M, Prezas P, Farthmann J, Baretton G, Luther T, Tjan-Heijnen VC, Talieri M, Schmitt M, Sweep FC, Span PN, Magdolen V.

Clin Chem. 2006 Jun;52(6):1070-9. Epub 2006 Apr 20.

36.

Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxynucleotides and siRNA.

Fuessel S, Herrmann J, Ning S, Kotzsch M, Kraemer K, Schmidt U, Hakenberg OW, Wirth MP, Meye A.

Cancer Lett. 2006 Feb 8;232(2):243-54.

PMID:
16458121
37.

Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast cancer.

Kotzsch M, Farthmann J, Meye A, Fuessel S, Baretton G, Tjan-Heijnen VC, Schmitt M, Luther T, Sweep FC, Magdolen V, Span PN.

Eur J Cancer. 2005 Nov;41(17):2760-8. Epub 2005 Oct 26.

PMID:
16256342
38.

Vascular endothelial growth factor antisense pretreatment of bladder cancer cells significantly enhances the cytotoxicity of mitomycin C, gemcitabine and Cisplatin.

Krause S, Förster Y, Kraemer K, Fuessel S, Kotzsch M, Schmidt U, Wirth MP, Meye A, Schwenzer B.

J Urol. 2005 Jul;174(1):328-31.

PMID:
15947684
39.

Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer.

Werle B, Kotzsch M, Lah TT, Kos J, Gabrijelcic-Geiger D, Spiess E, Schirren J, Ebert W, Fiehn W, Luther T, Magdolen V, Schmitt M, Harbeck N.

Anticancer Res. 2004 Nov-Dec;24(6):4147-61.

40.

Chemosensitization of bladder cancer cell lines by human telomerase reverse transcriptase antisense treatment.

Kraemer K, Fuessel S, Kotzsch M, Ning S, Schmidt U, Wirth MP, Meye A.

J Urol. 2004 Nov;172(5 Pt 1):2023-8.

PMID:
15540782
41.

siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth.

Ning S, Fuessel S, Kotzsch M, Kraemer K, Kappler M, Schmidt U, Taubert H, Wirth MP, Meye A.

Int J Oncol. 2004 Oct;25(4):1065-71.

PMID:
15375557
42.

Systematic in vitro evaluation of survivin directed antisense oligodeoxynucleotides in bladder cancer cells.

Fuessel S, Kueppers B, Ning S, Kotzsch M, Kraemer K, Schmidt U, Meye A, Wirth MP.

J Urol. 2004 Jun;171(6 Pt 1):2471-6.

PMID:
15126878
43.

Perfluorocarbon attenuates response of concanavalin A-stimulated mononuclear blood cells without altering ligand-receptor interaction.

Haufe D, Luther T, Kotzsch M, Knels L, Koch T.

Am J Physiol Lung Cell Mol Physiol. 2004 Jul;287(1):L210-6. Epub 2004 Mar 5.

44.

Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53.

Kappler M, Bache M, Bartel F, Kotzsch M, Panian M, Würl P, Blümke K, Schmidt H, Meye A, Taubert H.

Cancer Gene Ther. 2004 Mar;11(3):186-93.

PMID:
14739938
45.

Interleukin-1beta-induced expression of the urokinase-type plasminogen activator receptor and its co-localization with MMPs in human articular chondrocytes.

Schwab W, Schulze-Tanzil G, Mobasheri A, Dressler J, Kotzsch M, Shakibaei M.

Histol Histopathol. 2004 Jan;19(1):105-12. doi: 10.14670/HH-19.105.

PMID:
14702177
46.

Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells.

Kraemer K, Fuessel S, Schmidt U, Kotzsch M, Schwenzer B, Wirth MP, Meye A.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3794-800.

47.

Tissue specific expression and serum levels of human tissue factor in patients with urological cancer.

Förster Y, Meye A, Albrecht S, Kotzsch M, Füssel S, Wirth MP, Schwenzer B.

Cancer Lett. 2003 Apr 10;193(1):65-73.

PMID:
12691825
48.

Identification of a novel urokinase receptor splice variant and its prognostic relevance in breast cancer.

Luther T, Kotzsch M, Meye A, Langerholc T, Füssel S, Olbricht N, Albrecht S, Ockert D, Muehlenweg B, Friedrich K, Grosser M, Schmitt M, Baretton G, Magdolen V.

Thromb Haemost. 2003 Apr;89(4):705-17.

PMID:
12669126
49.

Elevated expression level of survivin protein in soft-tissue sarcomas is a strong independent predictor of survival.

Kappler M, Kotzsch M, Bartel F, Füssel S, Lautenschläger C, Schmidt U, Würl P, Bache M, Schmidt H, Taubert H, Meye A.

Clin Cancer Res. 2003 Mar;9(3):1098-104.

50.

Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets.

Müller I, Klocke A, Alex M, Kotzsch M, Luther T, Morgenstern E, Zieseniss S, Zahler S, Preissner K, Engelmann B.

FASEB J. 2003 Mar;17(3):476-8. Epub 2003 Jan 2.

PMID:
12514112

Supplemental Content

Loading ...
Support Center